Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Sponsor: Portland VA Research Foundation, Inc
This observational or N/A phase trial investigates Amphetamine-Related Disorders and is currently ongoing. Portland VA Research Foundation, Inc leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. Primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. An additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.
The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. Primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. An additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.
Status Flow
Change History
9 versions recorded-
Apr 23, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → None
-
Jan 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 4 earlier versions
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Contact Information
- Portland VA Research Foundation, Inc
- Steven & Alexandra Cohen Foundation
For direct contact, visit the study record on ClinicalTrials.gov .